After getting skunked by rivals, Pfizer touts ‘breakthrough’ cancer drug lorlatinib, heads to the FDA
Pfizer’s Xalkori has become a Phase III punching bag of sorts for top rivals in the cancer field. In June Novartis’ Zykadia picked up an FDA approval to challenge Xalkori in frontline ALK-positive lung cancer. And Roche’s Alecensa has been whupping up on Xalkori as well, proving better at cutting the risk of disease progression.
So it’s no wonder that Pfizer is taking its positive Phase II data — posted today — for its next-gen successor lorlatinib straight to regulators.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.